4-aminobenzoic acid has been researched along with Inflammation in 13 studies
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "CHF6001 is a novel inhaled phosphodiesterase-4 inhibitor." | 6.90 | Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. ( Beeh, KM; Colgan, B; Emirova, A; Geraci, S; Govoni, M; Kornmann, O; Leaker, B; Lucci, G; Nandeuil, MA; Singh, D; Watz, H, 2019) |
| "CHF6001 is a novel inhaled phosphodiesterase-4 inhibitor." | 2.90 | Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. ( Beeh, KM; Colgan, B; Emirova, A; Geraci, S; Govoni, M; Kornmann, O; Leaker, B; Lucci, G; Nandeuil, MA; Singh, D; Watz, H, 2019) |
| "CHF6001 is an inhaled PDE4 inhibitor, while inhaled ensifentrine is an inhibitor of both PDE3 and PDE4; antagonism of PDE3 facilitates smooth muscle relaxation and hence bronchodilation." | 2.72 | Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. ( Lea, S; Mathioudakis, AG; Singh, D, 2021) |
| "Acute inflammation is a protective response of the body to harmful stimuli, such as pathogens or damaged cells." | 1.46 | Targeting inflammasome by the inhibition of caspase-1 activity using capped mesoporous silica nanoparticles. ( Alcaraz, MJ; Aznar, E; Costero, AM; Ferrándiz, ML; García-Fernández, A; García-Laínez, G; Marcos, MD; Martínez-Máñez, R; Murguía, JR; Orzáez, M; Sancenón, F, 2017) |
| "Type 2 diabetes was induced in adult male rats by high-fructose/high-fat diet and low streptozotocin dose." | 1.46 | PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis. ( Ahmed, AF; Ali, AA; El-Bassossy, HM; El-Maraghy, NN; Zakaria, EM, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 7 (53.85) | 2.80 |
| Authors | Studies |
|---|---|
| Wen, S | 2 |
| Deng, F | 1 |
| Li, L | 1 |
| Xu, L | 1 |
| Li, X | 1 |
| Fan, Q | 1 |
| Singh, D | 2 |
| Lea, S | 1 |
| Mathioudakis, AG | 1 |
| Wu, S | 1 |
| Li, Z | 1 |
| Ye, M | 1 |
| Liu, C | 1 |
| Liu, H | 1 |
| He, X | 1 |
| Qin, Y | 1 |
| Liang, F | 1 |
| Pan, L | 1 |
| Lin, F | 1 |
| Beeh, KM | 1 |
| Colgan, B | 1 |
| Kornmann, O | 1 |
| Leaker, B | 1 |
| Watz, H | 1 |
| Lucci, G | 1 |
| Geraci, S | 1 |
| Emirova, A | 1 |
| Govoni, M | 1 |
| Nandeuil, MA | 1 |
| Wang, YH | 1 |
| Li, Y | 1 |
| Wang, JN | 1 |
| Zhao, QX | 1 |
| Wang, SC | 1 |
| Sun, T | 1 |
| Zhang, D | 1 |
| Liu, X | 1 |
| Dong, X | 1 |
| Zhu, R | 1 |
| Jiang, J | 1 |
| Ye, Y | 1 |
| Jiang, Y | 1 |
| Flores, J | 1 |
| Noël, A | 1 |
| Foveau, B | 1 |
| Beauchet, O | 1 |
| LeBlanc, AC | 1 |
| Wang, X | 1 |
| Wu, T | 1 |
| Ma, H | 1 |
| Huang, X | 1 |
| Huang, K | 1 |
| Ye, C | 1 |
| Zhu, S | 1 |
| Dan, T | 1 |
| Ichimura, A | 1 |
| Pelisch, N | 1 |
| Miyata, K | 1 |
| Akahori, K | 1 |
| Miyata, T | 1 |
| Zhang, Y | 1 |
| Liu, L | 1 |
| Liu, YZ | 1 |
| Shen, XL | 1 |
| Wu, TY | 1 |
| Zhang, T | 1 |
| Wang, W | 1 |
| Wang, YX | 1 |
| Jiang, CL | 1 |
| García-Fernández, A | 1 |
| García-Laínez, G | 1 |
| Ferrándiz, ML | 1 |
| Aznar, E | 1 |
| Sancenón, F | 1 |
| Alcaraz, MJ | 1 |
| Murguía, JR | 1 |
| Marcos, MD | 1 |
| Martínez-Máñez, R | 1 |
| Costero, AM | 1 |
| Orzáez, M | 1 |
| Zakaria, EM | 1 |
| El-Maraghy, NN | 1 |
| Ahmed, AF | 1 |
| Ali, AA | 1 |
| El-Bassossy, HM | 1 |
| Consoli, V | 1 |
| Alfieri, P | 1 |
| Betti, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-blind,Placebo Controlled, Repeated Dose, Three-way Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD[NCT03004417] | Phase 2 | 61 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for 4-aminobenzoic acid and Inflammation
| Article | Year |
|---|---|
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Aminopyridines; Animals; Benzamides; Cyclic AMP; Cyclopropanes; Humans; | 2021 |
Plasminogen activator inhibitor-1 (PAI-1) molecule: new physiological roles and clinical applications.
Topics: Aging; Animals; Blood Coagulation; Clinical Trials as Topic; Disease Models, Animal; Drug Discovery; | 2014 |
1 trial available for 4-aminobenzoic acid and Inflammation
| Article | Year |
|---|---|
Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.
Topics: Aged; Biomarkers; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doubl | 2019 |
10 other studies available for 4-aminobenzoic acid and Inflammation
| Article | Year |
|---|---|
VX-765 ameliorates renal injury and fibrosis in diabetes by regulating caspase-1-mediated pyroptosis and inflammation.
Topics: Animals; Caspase 1; Cell Culture Techniques; Diabetes Mellitus, Experimental; Diabetic Nephropathies | 2022 |
VX765, a Specific Caspase-1 Inhibitor, Alleviates Lung Ischemia Reperfusion Injury by Suppressing Endothelial Pyroptosis and Barrier Dysfunction.
Topics: Animals; Caspase 1; Caspase Inhibitors; Cells, Cultured; Dipeptides; Endothelial Cells; Inflammasome | 2021 |
A Novel Mechanism of Specialized Proresolving Lipid Mediators Mitigating Radicular Pain: The Negative Interaction with NLRP3 Inflammasome.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Caspase 1; Caspase Inhibitors; Dipeptides; Docosahexa | 2020 |
Cannabinoid 1 Receptor Antagonists Play a Neuroprotective Role in Chronic Alcoholic Hippocampal Injury Related to Pyroptosis Pathway.
Topics: Alcohol-Induced Disorders, Nervous System; Animals; Cannabinoid Receptor Agonists; Cannabinoid Recep | 2020 |
Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Cognitive Dysfunction; C | 2020 |
VX-765 ameliorates inflammation and extracellular matrix accumulation by inhibiting the NOX1/ROS/NF-κB pathway in diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Diabetes Mellitus, Experimental; Diabet | 2022 |
NLRP3 Inflammasome Mediates Chronic Mild Stress-Induced Depression in Mice via Neuroinflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Carrier Proteins; Caspase 1 | 2015 |
Targeting inflammasome by the inhibition of caspase-1 activity using capped mesoporous silica nanoparticles.
Topics: Animals; Anti-Inflammatory Agents; Caspase Inhibitors; Cell Line; Delayed-Action Preparations; Dipep | 2017 |
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
Topics: Animals; Benzamides; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2017 |
[Evaluation of the activity of aminaftone as coadjuvant treatment in various traumatic injuries].
Topics: 4-Aminobenzoic Acid; Adult; Aged; Aminobenzoates; Drug Evaluation; Drug Therapy, Combination; Female | 1985 |